Roche advances vamikibart toward FDA review as Roche Holding stock trades at EUR 392.85

Published on 10/13/2026 at 09:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche shared vamikibart data on October 10, 2026, with an FDA decision due July 2027. Roche Holding stock was EUR 392.85 on October 13, 2026.

Key points in brief

Roche advanced vamikibart toward FDA review after new one-year eye-disease data.
Two-thirds of eligible patients needed no retreatment after Week 16 in the reported analysis.
Roche Holding stock was at EUR 392.85 at Lang & Schwarz on October 13, 2026.
Roche scheduled its third-quarter sales presentation for October 22, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 392.85 at Lang & Schwarz on October 13, 2026 at 9:34 a.m. CEST as Roche advanced vamikibart toward FDA review. The company presented one-year data from two phase III studies, and Roche dated the release October 10, 2026.

Three milestones shape the pipeline

On September 21, 2026, Roche outlined a CHF 790 million investment in a Basel production project. Finanznachrichten reported that the new facility and modernization work are intended for synthetic active ingredients, with completion planned by 2030.

On September 22, 2026, phase II testing of enicepatide reduced the long-term blood-sugar measure by 2.65 percentage points at the highest tested dose, while average body weight fell 15.50 percent, Finanznachrichten reported.

What vamikibart adds

The October 10 update centers on vamikibart for uveitic macular edema, a serious inflammatory eye condition. At Week 52, a numerically higher share of patients achieved vision gains than those receiving sham treatment, while two-thirds of eligible patients required no retreatment after Week 16, according to Fierce Biotech on October 12, 2026.

The regulatory timetable gives the program a defined checkpoint: the FDA decision is expected in July 2027. Authorities in China, the European Union and Japan are also reviewing filings, while the trials previously produced one successful and one unsuccessful primary endpoint, keeping the development profile mixed.

Upcoming dates and stock context

Roche lists its third-quarter sales presentation for October 22, 2026, followed by the Berenberg Pharma CFO Series on November 2, 2026, on its investor calendar. The dates matter because the October sales update will provide the next company-wide operating checkpoint after the first-half report.

Roche Holding AG had a market capitalization of USD 296.5 billion as of October 12, 2026, according to structured market data. The company reported 2025 core earnings per share growth of 11.00 percent at constant exchange rates and core earnings per share of CHF 19.46 on its investor page, giving the pipeline news a profitability backdrop.

Roche Holding stock at Lang and Schwarz

Roche Holding stock was trading at EUR 392.85 at Lang & Schwarz on October 13, 2026 at 9:34 a.m. CEST. The quote was intraday during the regular Xetra trading phase.

The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.